AtaiBeckley to Participate in the Jefferies Global Healthcare Conference in London
Atai Beckley (NASDAQ: ATAI) will participate in the Jefferies Global Healthcare Conference in London.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Atai Beckley (NASDAQ: ATAI) will participate in the Jefferies Global Healthcare Conference in London.
Who: Srinivas Rao, M.D., Ph.D., CEO, and Kevin Craig, M.D., CMO. Format: Fireside chat and one-on-one investor meetings. When: Fireside chat on Thursday, November 20, 2025 at 11:30 A.M. GMT / 6:30 A.M. ET. Webcast: A live webcast is provided and an archived replay will be available on the company Investors Events page for up to 90 days.
Details
News Market Reaction – ATAI
On Nov 13, the day this news came out, ATAI closed 4.62% below the previous close.
Data tracked by StockTitan Argus for the Nov 13 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK and AMSTERDAM, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced that Srinivas Rao, M.D., Ph.D., Co-Founder and Chief Executive Officer, and Kevin Craig, M.D., Chief Medical Officer, are scheduled to participate in the Jefferies Global Healthcare Conference in London, UK. Details of the company’s participation:
Format: Fireside chat and 1x1 investor meetings
Date and Time: Fireside chat on Thursday, November 20 at 11:30 A.M. GMT/ 6:30 A.M. ET
Webcast link: Here
An archived replay will be available on the Investors section of the AtaiBeckley website under Events for up to 90 days.
About Atai Beckley N.V.
AtaiBeckley is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments. It was formed through the strategic combination of atai Life Sciences N.V. and Beckley Psytech Limited in November 2025. AtaiBeckley’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (buccal film DMT) for TRD and EMP-01 (oral R-MDMA) for social anxiety disorder, which are in Phase 2 clinical development. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. These programs aim to create new possibilities in mental health by providing effective, commercially scalable and convenient interventional psychiatry therapies that can integrate seamlessly into healthcare systems.
For the latest updates and to learn more about the AtaiBeckley mission, visit www.ataibeckley.com or follow the Company on LinkedIn and on X.
Contact Information
Investor Contact:
IR@ataibeckley.com
Media Contact:
PR@ataibeckley.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.